Asahi Kasei receives Japanese regulatory approval for Xiaflex in Dupuytren's contracture

20 July 2015

Japanese pharma company Asahi Kasei has received approval for its regulatory application to the Japanese Pharmaceutical and Medical Device Agency for Xiaflex (collagenase clostridium histolyticum) to treat Dupuytren’s contracture in Japan.

Asahi has the rights to develop and market Xiaflex in Japan through an agreement with Endo International, a partner of BioSpecifics Technologies (Nasdaq: BSTC). BioSpecifics will receive a milestone payment upon the commercial launch in Japan.

Thomas Wegman, president of BioSpecifics, said: "This approval in Japan marks another milestone in our globalization strategy for Xiaflex and we look forward to the upcoming commercial launch. We believe Asahi Kasei's strong development and commercialization organizations will greatly enhance the sales potential of Xiaflex in this region. We are very happy that these patients now have a minimally-invasive non-surgical treatment option available to them."

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK